RA Capital Management

Attention #biotech entrepreneurs and researchers! Don’t miss your chance to pitch your #startup ideas at #Science2Startup 2025 to top biotech and #pharma executives, VCs, and entrepreneurs in the Boston area. Applications are due Friday, November 15th: https://lnkd.in/e7bPwMzX

Congratulations to Endpoints11 winner and RA Capital Management-backed Capstan Therapeutics on being recognized for their efforts to try to win the #invivo #CAR-T race! Per Endpoints News, "turning a patient’s own cells into powerful disease combatants — without the complexity of removing them from the body to do so — was a fantasy. Now it’s getting closer to reality." Congratulations to Laura Shawver and the team for being selected as a representation of what Endpoints News calls the "biggest bets, most interesting science and technology, and strongest leadership teams in the industry." https://lnkd.in/ejtXNpUQ

It's a big Monday out there: congratulations to the team Aktis Oncology on their $175MM oversubscribed Series B financing! We were proud to lead the financing along with co-leads RTW Investments, LP investments and Janus Henderson Investors. We look forward to supporting Aktis Oncology's continued efforts to discover and develop novel targeted alpha radiopharmaceuticals to treat a broad range of solid tumors. Andrew Levin, MD, PhD, Partner and Managing Director at RA Capital Management, had this to say: “Aktis has leveraged its unique technology platform, experienced team, robust supply chain and radiopharmaceutical development capabilities to generate a promising and differentiated pipeline of next-generation radiopharmaceuticals. We are pleased to support Aktis through the next stage of its growth as it seeks to bring new options to patients with cancer.” Here's the official release: https://lnkd.in/eYANNP84 #radiopharmaceuticals #oncology #innovation #biotech

Science2Startup 2025 applications are open now! https://lnkd.in/e7bPwMzX   Last year #Science2Startup brought together academic researchers, entrepreneurs, industry leaders, and venture capitalists for a dynamic exchange of ideas. Learn more by watching our video recap below.

Today, we are announcing the addition of credit and structured capital solutions to our platform, and we welcome industry veterans Jeremy Lack and Adam Kaye to lead the structured capital solutions team as Senior Managing Directors and Partners, Structured Capital. Augmenting our platform with structured capital solutions enables us to more comprehensively serve the capital needs of private and public healthcare companies through flexible equity, debt, royalty, and hybrid financing solutions. We are thrilled to welcome Jeremy and Adam to spearhead this new strategy as we offer the full range of capital to help innovative healthcare companies grow and bring life saving therapies to patients. Full release here: https://lnkd.in/gVjyRdqH #innovation #healthcare

Last year, #Science2Startup brought together academic researchers, entrepreneurs, industry leaders, and venture capitalists for a dynamic exchange of ideas. The symposium showcased eight exceptional scientists from leading global research institutions, all working on pioneering advancements in science. To learn more about the event or to get involved for our 2025 event this May, please email us at info@science2startup.com or visit www.science2startup.com.   #biotech #pharma #startup

The team at Superluminal Medicines Inc. is working to transform how medicines are created with their generative biology, chemistry, and machine learning platform. We were excited to lead their recent $120 million Series A funding round, with participation from Insight Partners, nVentures (NVIDIA), Gaingels, and new investors Catalio Capital Management, Eli Lilly and Company, and Cooley LLP. We look forward to Superluminal Medicines Inc. continuing their important work!

Ever stumble into something and think “holy ****, how does everyone not realize this is here?” That’s what gateway.racap.com is for biotech executives/directors and everyone who wants to be one. It’s still an emerging gem where my colleagues and I have been storing pearls in the form of interviews and articles and slide decks that explain countless things about biotech. You can even assess the strength of your board across 20+ dimensions & discover people who could fill gaps. Learn how to run efficient board meetings (shave 4 hours down to 1-2; hint: elephant slide, core value prop, and agenda), how low fees could be on financing instruments, real differences between crossover and other rounds, how to teach value of equity to employees, how to extract from your existing investors what they really want to invest in an IPO and at what price, how to handle M&A negotiations, the utility of low-ego polymaths, how to avoid overstaffing, and so much more. When we learn new things, Gateway is where we share what we learn. And if you have something you want to teach, just let me know. Gateway features the wisdom of many people from across our ecosystem. I wrote “The Entrepreneur’s Guide to a Biotech Startup” 20 years ago. Gateway is the ever evolving sequel. Hope you discover it (if you haven’t already) and pass it onto to others. Because we all make fewer mistakes when we learn from others. And with society demanding that we do more with less, there’s really no excuse for repeating mistakes, right? Peter #biotech RA Capital Management

Congratulations to the team at Vesta Healthcare! We were excited to lead this financing, and we look forward to their continued work to improve healthcare outcomes for those with home care needs.

We are excited to announce the first acquisition of a fully-baked company from RA Capital's RAVen (RA Ventures) incubator - congratulations to the Mariana Oncology team! You can read more about how RAVen helped build the company that became Mariana in the RApport article below. https://lnkd.in/eQmjvZQu